Perioperative adebrelimab with S-1 and oxaliplatin for locally advanced gastric or gastroesophageal junction cancer

A Randomized, Double-blind, Multicenter Phase III Trial of Adebrelimab (SHR-1316) Plus S-1 and Oxaliplatin (SOX) Versus Placebo Plus S-1 and Oxaliplatin in the Perioperative Treatment of Resectable Gastric or Gastroesophageal Junction Cancer

This trial tests whether adding the immunotherapy adebrelimab to standard chemotherapy (S-1 and oxaliplatin) given around surgery can help people with locally advanced stomach or gastroesophageal junction cancer stay free of cancer events longer.

Quick facts

• Phase: Phase 3
• Study type: Interventional
• Enrollment: 874 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd (Industry-sponsored)
• Drugs / interventions: adibelimab, chemotherapy, immunotherapy, Adebrelimab
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT07522151 on ClinicalTrials.gov

What this trial studies

This is a randomized, double-blind, multicenter phase III trial comparing adebrelimab plus S-1 and oxaliplatin versus placebo plus S-1 and oxaliplatin in the perioperative (neoadjuvant plus surgery) setting for locally advanced gastric or gastroesophageal junction cancer. The primary endpoint is event-free survival, with secondary assessments of overall efficacy, safety, and tolerability of the two combination regimens. Eligible participants are adults 18–74 years old with pathologically confirmed disease, ECOG 0–1, adequate organ function, and available tumor tissue. The trial is sponsored by Shanghai Shengdi Pharmaceutical and includes at least Beijing Cancer Hospital as a participating site.

Who should consider this trial

Good fit: Ideal candidates are adults 18–74 with pathologically confirmed locally advanced gastric or gastroesophageal junction cancer planned for neoadjuvant therapy followed by curative surgery, with ECOG performance 0–1 and adequate organ and bone marrow function.

Not a fit: Patients with metastatic disease, poor performance status, serious organ dysfunction, or those not planning curative surgery are unlikely to benefit from this perioperative regimen.

Why it matters

Potential benefit: If successful, adding adebrelimab could reduce recurrence and extend the time patients remain free of cancer events after perioperative chemotherapy and surgery.

How similar studies have performed: Other trials adding PD-1/PD-L1 immune checkpoint inhibitors to chemotherapy in gastric/GEJ cancer have shown mixed but sometimes positive results, supporting this general approach though outcomes vary by setting and biomarker status.

Eligibility criteria

Inclusion Criteria:

1. Patients with pathologically confirmed gastric cancer or gastroesophageal junction cancer.
2. Age: ≥18 years old, \<75 years old, both male and female are eligible.
3. Before entering the study, the investigator has evaluated and determined that the subject is suitable and plans to undergo neoadjuvant therapy + radical surgery for curative purposes.
4. Gastric cancer or gastroesophageal junction cancer applicable to the 8th edition of the AJCC gastric cancer staging criteria.
5. Fresh specimens (preferred) or formalin-fixed, paraffin-embedded tumor tissue blocks or unstained tumor specimen sections obtained within 6 months before randomization can be provided.
6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1.
7. Expected survival ≥ 6 months.
8. Adequate organ and bone marrow function.
9. Female subjects are either infertile or fertile, with a negative serum pregnancy test result within 3 days before the start of study medication and not in the lactation period. Fertile female subjects and male subjects whose partners are fertile must agree to avoid sperm/egg donation from the time of signing the informed consent form until 6 months after the last administration of the investigational drug, and comply with relevant contraceptive requirements.
10. Consent has been obtained from the individual and the informed consent form has been signed, willing and able to comply with planned visits, study treatment, laboratory tests, and other trial procedures.

Exclusion Criteria:

1. Gastric cancer known to be squamous cell carcinoma, undifferentiated carcinoma or other histological types, or adenocarcinoma mixed with other histological types.
2. Gastric esophageal junction cancer, Siewert type I; or Siewert type II with esophageal invasion length ≥ 4 cm; or other cases not suitable for clinical staging assessment using the 8th edition of the AJCC gastric cancer staging criteria, or not suitable for conventional surgical methods or approaches for gastric cancer.
3. The subject's weight has decreased by more than 20% within 2 months before randomization.
4. Previous anti-tumor treatment for gastric cancer/gastric esophageal junction cancer (including chemotherapy, radiotherapy, immunotherapy, endocrine therapy, targeted therapy, biological therapy or tumor embolization).
5. Known allergy to any component of the investigational drug (including adibelimab/placebo, tegafur, and oxaliplatin), or allergy to humanized monoclonal antibody products.
6. Diagnosis of any other malignant tumor within 5 years before entering the study, except for locally treatable and cured skin basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, ductal carcinoma in situ of the breast, and papillary thyroid carcinoma.
7. History of immunodeficiency (including positive HIV test, other acquired or congenital immunodeficiency diseases) or organ transplantation (including allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation, etc.); history of active autoimmune disease, except for immune disorders that do not require systemic treatment (such as vitiligo, psoriasis, etc.) or autoimmune diseases that can be improved through hormone replacement therapy (such as type 1 diabetes or hypothyroidism).
8. Severe, unhealed or open wounds, active ulcers, or untreated fractures.
9. Active severe digestive system diseases.
10. Presence of interstitial pneumonia or interstitial lung disease.
11. Severe cardiovascular or metabolic diseases.
12. Active HBV or HCV infection (HBsAg positive and viral copy number ≥ 2000 IU/mL, HCV antibody positive and HCV RNA above the upper limit of normal at the research center), or co-infection with hepatitis B and hepatitis C.
13. Active tuberculosis infection within 1 year before randomization (including but not limited to pulmonary tuberculosis, intestinal tuberculosis, etc.), or a history of active tuberculosis infection more than 1 year ago but without regular treatment.
14. Severe infection within 4 weeks before randomization.
15. Known history of abuse of psychotropic drugs or drug addiction.
16. Presence of other serious physical or mental diseases or abnormal laboratory tests that may increase the risk of participation in the study, or interfere with the study results, and patients considered unsuitable for participation in the study by the investigator.

Where this trial is running

Beijing, Beijing Municipality

• Beijing Cancer Hospital — Beijing, Beijing Municipality, China (Recruiting)

Study contacts

• Study coordinator: Bin Bai

Conditions Locally Advanced Gastric or Gastroesophageal Junction Cancer